Conmed Corp (CNMD) Stock
Key stats
- Market cap
- $1.51B
- Price / Earnings ratio
- 20.8x
- EPS (TTM)
- $2.42
- Volume
- Loading
- 52-week high
- $54.80
- 52-week low
- $31.44
Source: third-party data provider, as of November 13, 2026
Compare with CNMD
Recent news

CONMED Corporation to Participate in the Jefferies Global Healthcare Conference
CONMED Corporation to Participate in the Jefferies Global Healthcare Conference
CNMD

CONMED Q3 Earnings Call Highlights
CONMED Q3 Earnings Call Highlights
CNMD

Conmed (CNMD) Q3 Earnings Top Estimates
Conmed (CNMD) Q3 Earnings Top Estimates
CNMD

Here's What Key Metrics Tell Us About Conmed (CNMD) Q3 Earnings
Here's What Key Metrics Tell Us About Conmed (CNMD) Q3 Earnings
CNMD
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 57.59
- MACD 12/26/9
- 1.32
- EMA 9 of MACD
- 0.89
- MACD histogram
- 0.43
- SMA 50
- $47.12
- Price above SMA 50
- EMA 50
- $47.49
- Price above EMA 50
- SMA 200
- $41.78
- Price above SMA 200
- EMA 200
- $43.13
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.10 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

CONMED Corporation to Participate in the Jefferies Global Healthcare Conference
CONMED Corporation to Participate in the Jefferies Global Healthcare Conference
CNMD

CONMED Q3 Earnings Call Highlights
CONMED Q3 Earnings Call Highlights
CNMD

Conmed (CNMD) Q3 Earnings Top Estimates
Conmed (CNMD) Q3 Earnings Top Estimates
CNMD

Here's What Key Metrics Tell Us About Conmed (CNMD) Q3 Earnings
Here's What Key Metrics Tell Us About Conmed (CNMD) Q3 Earnings
CNMD

CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
CNMD

CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026
CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026
CNMD

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CNMD

Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?
Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?
CNMD

CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
CNMD

CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last
CNMD
News tone: automated (AI) classification of the article's content, not a price prediction.
About Conmed Corp
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Patrick J. Beyer | President, CEO & Director | 1966 |
| Mr. John E. Gallagher III | Executive VP, CFO and Principal Financial & Accounting Officer | 1973 |
| Ms. Hollie K. Foust | Executive VP, General Counsel & Corporate Secretary | 1975 |
| Mr. Peter K. Shagory | Executive Vice President of Strategy & Corporate Development | 1969 |
| Mr. Todd W. Garner CPA | Advisor | 1969 |
| Mr. Brent Lalomia | Executive VP of Regulatory Affairs, Quality Assurance, Clinical Affairs, Commercial Operations & IT | 1975 |
| Mr. Josep Lluis Llorens | Executive VP Global Supply Chain Management & Operations | 1963 |
| Mr. Richard Glaze | Chief Information Officer | 1966 |
| Keith Seaton | Vice President of Compliance | — |
| Mr. John David Ferrell | Executive Vice President of Human Resources | 1968 |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 57.59
- MACD 12/26/9
- 1.32
- EMA 9 of MACD
- 0.89
- MACD histogram
- 0.43
- SMA 50
- $47.12
- Price above SMA 50
- EMA 50
- $47.49
- Price above EMA 50
- SMA 200
- $41.78
- Price above SMA 200
- EMA 200
- $43.13
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $49.00
- Average
- $49.50
- High
- $50.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -12.9 | +8.1 | ||||||||||
| 2022 | -5.7 | +4.9 | +2.8 | -11.2 | -13.2 | -14.3 | +0.8 | -9.2 | -8.5 | -2.4 | +4.8 | +1.3 |
| 2023 | +6.7 | -3.1 | +8.0 | +22.4 | -3.6 | +9.8 | -9.8 | -5.7 | -8.7 | -1.9 | +8.7 | -0.1 |
| 2024 | -13.2 | -4.1 | +0.2 | -13.9 | +11.9 | -10.2 | +3.1 | +12.1 | +1.1 | -0.1 | +5.2 | -9.9 |
| 2025 | +6.6 | -16.9 | +3.5 | -17.3 | -0.8 | -6.0 | -5.4 | +4.0 | -12.2 | -6.7 | -3.2 | -8.8 |
| 2026 | -5.3 | +17.3 | -22.8 | +3.2 | -3.0 | -5.5 | +41.3 | -3.9 | -5.9 | -3.6 | +9.0 |
Corporate actions
Upcoming
No upcoming corporate actions for CNMD



